Toggle Nav

CCT251545

In stock
Catalog No.
B5979
Orally bioavailable and potent WNT signaling inhibitor
Grouped product items
SizePriceStock Qty
5mg
$150.00
In stock
10mg
$250.00
In stock
20mg
$350.00
In stock
50mg
$650.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM [1].

The WNT signaling network controls cellular functions such as proliferation and differentiation, and is a major regulator of mammalian development. WNT signaling is frequently deregulated in malignancy, especially in colon cancer, and plays an important role in the generation and maintenance of cancer stem cells [1].

CCT251545 is an orally bioavailable and potent WNT signaling inhibitor discovered through high-throughput cell-based screening. CCT251545 is also a potent and selective chemical probe for the human Mediator complex-associated protein kinases CDK8 and CDK19. CCT251545 changed gene expression regulated by WNT pathway and other on-target effects of modulating CDK8 and CDK19, including expression of genes regulated by STAT1 [2]. CCT251545 also inhibited GSK3α and -β with IC50 values of 0.462 and 0.690 μM. In APC mutant human colorectal cancer cell line (COLO205-F1756 clone 4), CCT251545 inhibited WNT pathway activity with IC50 value of 0.035 nM [1].

In both mouse and rat, CCT251545 exhibited moderate clearance with moderate to high oral bioavailability. In mice bearing COLO205-F1756 clone 4 tumor xenografts, CCT251545 (70 mg/kg po bid for 9 days) significantly inhibited WNT signaling and reduced tumor weights by 37.5% [1].

References:
[1].  Mallinger A, Crumpler S, Pichowicz M, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem, 2015, 58(4): 1717-1735.
[2].  Dale T, Clarke PA, Esdar C, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol, 2015, 11(12): 973-980.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt421.92
Cas No.1661839-45-7
FormulaC23H24ClN5O
Solubility≥42.2mg/mL in DMSO
Chemical Name8-(3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
SDFDownload SDF
Canonical SMILESO=C(NCC1)C1(CC2)CCN2C3=C(C4=CC=C(C5=CN(C)N=C5)C=C4)C=NC=C3Cl
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment [1]:

Cell lines

APC mutant human colorectal cancer cell line (COLO205-F1756 clone 4)

Preparation method

This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0.035 μM

Applications

In COLO205-F1756 clone 4, CCT251545 potently inhibited WNT pathway activity, with the IC50 value of 0.035 μM. Moreover, CCT251545 did not affect endogenous levels of TCF1 or TCF4.

Animal experiment [1]:

Animal models

Mice bearing COLO205-F1756 clone 4 xenografts

Dosage form

70 mg/kg; p.o.; b.i.d., for 9 days

Applications

In mice bearing COLO205-F1756 clone 4 xenografts, CCT251545 (70 mg/kg; p.o.; b.i.d., for 9 days) substantially inhibited WNT signaling and reduced tumor weights by 37.5%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Mallinger A, Crumpler S, Pichowicz M, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem, 2015, 58(4): 1717-1735.

Quality Control